Physician profile

F Matthew Smith

Plastic Surgery · Traverse City, MI

NPI 1285614032

$15,450.42

in general payments reported to CMS, 2019-2025

8 companies · $14.00 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$1,611.62
Food and Beverage$491.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Kls-Martin L.P. $13,147.81 2022
Abbvie INC. $2,103.60 2023-2025 Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps, Alloderm
Allergan, INC. $100.06 2019-2021
Sientra, INC. $28.88 2022
Stryker Corporation $25.60 2019
Tela Bio, INC. $18.11 2022
Medtronic USA, INC. $13.96 2019
Integra Lifesciences Corporation $12.40 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

F Matthew Smith

$15,450.42

in general payments reported 2019-2025

Years
2019-2025
Top company
Kls-Martin L.P.

https://glasscript.com/doctor/485905/f-matthew-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.